K
aposi's sarcoma (KS) is a highly vascular tumor that strictly requires infection with human herpesvirus-8 (HHV-8), also known as the KS-associated herpesvirus (KSHV) (1) . KSHV was first isolated from human AIDS-KS lesions (2) and later found to be associated with other forms of KS (classic, endemic, and iatrogenic) (3, 4) . In addition to endothelial (or endothelial precursor) cells, KSHV also infects lymphocytes and has been identified as the etiological agent for two lymphoproliferative disorders: primary effusion lymphomas (PELs) and multicentric Castleman's disease (5) .
Historically, KS was a benign and indolent tumor; however, KS often manifests as a more aggressive disseminated cancer in patients coinfected with HIV. Despite the decline in its incidence with the introduction of highly active antiretroviral therapies (HAARTs), KS continues to be an important cause of morbidity in patients with AIDS (6) . Furthermore, this tumor has emerged as one of the most common cancers in children and adult men in parts of the developing world where seroprevalence for KSHV and HIV remains high. Unfortunately, treatment of KS has proven to be challenging and is often only palliative. Current treatment options include chemotherapeutic drugs, which are themselves associated with acute and cumulative toxicity. Ongoing efforts are now focused on identifying more effective molecular-based therapies for the treatment of this enigmatic neoplasm.
KS is commonly multifocal, with lesions predominately affecting the skin and oral mucosa. However, visceral and lymph node involvement may occur in the most aggressive presentations.
Histopathologically, KS is characterized by a prominent angiogenic and exudative phenotype (7) . Proliferating tumor (spindle) cells surrounding abnormal vascular slits, erythrocyte extravasation, and profuse edema are all principal histological features of KS. These features are also responsible for the morbidity often associated with these lesions. Of note, the prominent vascularity of KS tumors has been attributed to the paracrine release of angiogenic mediators (e.g., vascular endothelial growth factor, or VEGF) by the KS spindle cells (8) . Indeed, VEGF and its receptor, VEGFR2 (KDR), are up-regulated in AIDS-KS primary lesions as well as in AIDS-KS spindle-cell cultures (9) (10) (11) (12) . Interestingly, both VEGF and KDR are also up-regulated by the KSHV-encoded viral G protein-coupled receptor, (vGPCR; ORF74), the viral oncogene thought to play an essential role in the initiation and promotion of KS (13) (14) (15) . Collectively, these observations have reinforced the assertion that VEGF is responsible for the increased vascular permeability observed in this tumor. However, the relative contribution of other angiogenic factors to the exudative phenotype of KS lesions remains unclear. We therefore set out to identify the key mediators that promote the increased vascular leakage characteristic of KS.
Results

VEGF Is Not Sufficient for the Exudative Phenotype in vGPCR Tumorigenesis.
To study the contribution of KSHV candidate oncogenes to KS development, we previously engineered a transgenic mouse model enabling retroviral transduction of genes to the vascular endothelium of mice (16) . Using this approach, we identified a single gene, the KSHV G protein-coupled receptor (vGPCR), capable of producing angioproliferative tumors in mice remarkably similar to human KS (16) . Careful examination of vGPCR lesions show whorls of spindle-shaped tumor cells surrounded by abundant irregular vascular channels lined by atypical endothelium, and characterized by increased vascular permeability, histologically identical to human KS (Fig. 1 A-E) . These features ultimately play a central role in the morbidity associated with KS lesions.
We therefore set out to study the molecular mechanism whereby vGPCR contributes to the exudative phenotype in KS tumors. To this end, we investigated whether expression of vGPCR in cultured endothelial cells promoted the disruption of the endothelial cell barrier. For this purpose, we used a tetracycline-inducible (Tet-on) system to express vGPCR in human primary dermal microvascular endothelial cells (HVMECs; Fig. 1F ). When vGPCR expression was induced in HMVECs, we observed a dramatic increase in enAuthor contributions: S.M. designed research; T.M., B.C.J., J.H., E.R.F., J.R.B., A.M., and A.S. performed research; T.M., B.C.J., A.S., and S.M. analyzed data; and T.M., B.C.J., A.M., A.S., and S.M. wrote the paper.
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This article is a PNAS Direct Submission. 1 To whom correspondence should be addressed. E-mail: smontaner@umaryland.edu. dothelial cell permeability (Fig. 1G) . Of note, it has been reported that vGPCR is an angiogenic activator by inducing the transcription and secretion of VEGF (14, 17) . Indeed, we found that VEGF is secreted by HMVECs upon expression of vGPCR (Fig. 1H ). We therefore examined the contribution of VEGF to the promotion of vascular permeability induced by vGPCR. Surprisingly, despite prior reports suggesting that VEGF binding to VEGFR-2 (KDR) was responsible for vGPCR promotion of angiogenesis (14, 15, 17) , inhibition of VEGF expression with siRNA ( Fig. 1I ) or pretreatment of HMVECs with a KDR inhibitor, su1498 (Fig. 1J) , only partially inhibited the vascular leakage induced by vGPCR expression. This suggested that VEGF may not be the only mediator promoting the breakdown of the integrity of the endothelial barrier in KS.
vGPCR Up-Regulates Angiopoietin-Like 4 Expression and Secretion in Vitro and in Vivo. We set out to identify additional paracrine factors that may be contributing to the exudative phenotype promoted by vGPCR. To this end, we explored the change in expression of angiogenesis-related genes induced by this viral receptor in endothelial cells using the Oligo GEArray Mouse Angiogenesis Microarray (SABiosciences), which profiles the expression of 113 key angiogenesis-related genes. Genes induced in murine immortalized endothelial cells (SVEC) stably expressing vGPCR, compared with the parental line (SVEC), are presented in Table S1 and include up-regulation of genes previously shown to be induced by vGPCR expression (18) . Of interest, this microarray analysis showed a robust up-regulation (13.14-fold) of the expression of angiopoietin like-4, a member of the family of Angiopoietin-like proteins (ANGPTLs) (19) . Induction of vGPCR expression in both immortalized (HMEC1) or primary (HMVEC) human dermal microvascular endothelial cells correlated with a potent up-regulation of angptl4 mRNA levels, and translation and secretion of ANGPTL4 ( Fig. 2A) . Furthermore, immunohistochemical staining of murine vGPCR tumors (16) as well as human AIDS-KS show high levels of expression of ANGPTL4 in the cells of these lesions, consistent with a role for this protein in Kaposi's sarcomagenesis (Fig. 2B) . Expression of ANGPTL4 was noted in most of the tumor cells, despite expression of vGPCR in only a few cells in both human and experimental (mouse) KS tumors (Fig. 2B ). This suggested that vGPCR may promote expression of ANGPTL4 through a paracrine mechanism.
To confirm that vGPCR expression is required for ANGPTL4 expression in these lesions, we used a KS tumor allograft model in which vGPCR is coexpressed with the Herpes simplex virus 1 thymidine kinase (TK) in murine endothelial cells (vGPCR/TK), rendering these cells exquisitely sensitive to treatment with the cyclic guanidine analog, ganciclovir (20) . vGPCR/TK tumors showed a robust expression of ANGPTL4 as (control) vGPCR allografts did (Fig. 2C) . However, treatment of mice with established vGPCR/TK tumors with ganciclovir led to the selective elimination of the vGPCR-expressing cells within the lesions (20) , and a progressive decrease in the levels of ANGPTL4 (Fig. 2C) , highlighting the dependence of ANGPTL4 secretion on vGPCR expression in vivo. Collectively, these findings suggest that vGPCR potently up-regulates the expression and secretion of ANGPTL4 in vitro and in vivo.
vGPCR Up-Regulation of ANGPTL4 Promotes Angiogenesis. Compelling data suggests that vGPCR induces sarcomagenesis through the release of pro-and antiangiogenic cytokines, chemokines, and growth factors that ultimately promote the proangiogenic and proexudative response induced by this viral receptor (8, 13) . In this regard, ANGPTL proteins have been previously shown to regulate multiple aspects of endothelial cell function, including endothelial cell proliferation, migration, differentiation, and endothelial cell adhesion (19) . However, conflicting data exists as to the pro-vs. antiangiogenic effects of ANGPTL4 (21) (22) (23) (24) (25) (26) . To elucidate the contribution of ANGPTL4 to the angiogenic switch promoted by vGPCR, we used the directed in vivo angiogenesis assay (DIVAA), which examines the development of blood vessels within basement membrane extract (BME)-filled angioreactors implanted in immunosuppressed mice (27) . For these experiments, we obtained conditioned media from endothelial cells expressing vGPCR, in the presence or absence of a specific siRNA for ANGPTL4. We also obtained vGPCR supernatants deficient in VEGF expression, using a specific VEGF siRNA, to contrast the role of ANGPTL4 to the one of this well-established vGPCR proangiogenic factor. Levels of secretion of ANGPTL4 and VEGF in the corresponding conditioned media are shown in Fig. S1 . When we assessed blood vessel growth induced by these supernatants, we found that vGPCR-conditioned media promoted a potent angiogenic response, which was prevented when we inhibited expression of ANGPTL4 using siRNA (Fig. 3A) . These effects were similar to that seen when we used siRNA to inhibit VEGF expression. Conversely, a positive angiogenic response was induced by treatment of endothelial cells with media conditioned by cells overexpressing ANGPTL4 or recombinant human ANGPTL4 (Fig. 3A) . Collectively, these findings suggest that ANGPTL4 may be a key factor in the promotion of neovascularization triggered by vGPCR.
Because endothelial cell proliferation, migration, and differentiation are essential steps of the angiogenic process, we next examined the effects of ANGPTL4 from vGPCR paracrine secretions on the regulation of these cellular functions. Inhibition of VEGF expression, but not ANGPTL4 expression, using siRNA partially inhibited endothelial cell proliferation (Fig. 3B) . However, inhibition of ANGPTL4 expression was able to prevent both endothelial cell migration as well as endothelial cell differentiation induced by vGPCR secretions ( Fig. 3C and D) . Of note, these effects were similar to that seen by inhibition of VEGF expression. In line with these findings, exposure to media conditioned by endothelial cells overexpressing ANGPTL4 or treatment with human recombinant ANGPTL4 resulted in an induction of endothelial cell migration (Fig. 3C ) and differentiation ( Fig. 3D ), but not proliferation (Fig. 3B) . Collectively, these findings suggest that ANGPTL4 is comparable to VEGF in its contribution to the promotion of angiogenic phenotype by vGPCR. Emerging evidence suggests that ANGPTL4 may play a role in vessel permeability (28, 29) . This prompted us to assess the relative contribution of this factor to the exudative phenotype of KS lesions. We therefore exposed confluent endothelial cells to vGPCR supernatants containing or deficient in ANGPTL4 and determined the passage of FITC-dextran through the cells. As shown in Fig. 4A , exposure of HMVEC monolayers to vGPCR secretions resulted in an increase in vascular permeability. Interestingly, this effect was blocked when confluent cells were exposed to ANGPTL4-deficient vGPCR supernatants (Fig. 4A) . Again, the reduction in vascular permeability promoted by ANGPTL4-deficient vGPCR supernatants was similar to that seen using VEGF-deficient vGPCR supernatants. These findings suggest that ANGPTL4, like VEGF, is critical for the induction of vascular leakage by vGPCR. To further explore the role of ANGPTL4 on the disruption of endothelial cell-cell junctions, we examined the expression of the tight junction component zonula occludens 1 (ZO-1) and the adherens junction component β-catenin in confluent HMVEC exposed to ANGPTL4. Figure 4B shows that the integrity of the endothelial monolayer was dramatically disturbed in the presence of ANGPTL4 or vGPCR conditioned media.
We next set out to assess the molecular mechanism whereby ANGPTL4 promotes vessel permeability. In this regard, it has been reported that the RhoA, Rac1, and Cdc42 small GTPases, key regulators of actin cytoskeleton dynamics, play a major role in vascular processes such as endothelial cell motility, angiogenesis, and endothelial cell permeability (30) . When we investigated the activation of these GTPases by ANGPTL4, we found an induction of RhoA and Cdc42 activity in treated endothelial cells (Fig. 4C) . Consistent with these observations, staining of the actin cytoskeleton with phalloidin showed the formation of stress fibers as well as filopodia in HMVEC cells exposed to ANGPTL4 (Fig. 4D) . Moreover, promotion of vessel permeability by this factor was inhibited by pretreatment of HMVEC monolayers with an inhibitor of RhoA activation, C3 toxin, or the HA1077 inhibitor for the RhoA downstream effector, ROCK (Fig. 4E) . Collectively, these findings suggest that ANGPTL4 induces vessel permeability through a mechanism dependent on Rho and ROCK.
ANGPTL4 Is Required for vGPCR Promotion of Angiogenesis, Vessel
Permeability, and Tumorigenesis. To assess the role of ANGPTL4 in vGPCR sarcomagenesis in vivo, we stably expressed a shRNA for ANGPTL4, to block endogenous ANGPTL4 expression, in immortalized murine endothelial cells also stably expressing vGPCR. Cell lines expressing vGPCR along with the ANGPTL4 shRNA (ANGPTL4 sh1 and ANGPTL4 sh2) showed decreased expression of this protein (Fig. 5A ) and reduced ability to form colonies in soft agar in vitro (Fig. S2) . We then took advantage of a recently developed allograft-based KS model, in which endothelial cells expressing vGPCR are mixed with endothelial cells stably expressing two KSHV latent genes, vCyclin and vFlip, in a (1:10) ratio that approximates the proportion of expressing cells found in human KS (20) . We injected nude mice with mixed populations of vCyc/vFlip-expressing cells along with vGPCR-expressing cells or vGPCR-expressing cells also expressing ANGPTL4 shRNA, to generate mixed cell tumor allografts (Fig. 5A) . vCyc/vFlip-expressing cells are not capable of forming tumors per se (20) . However, these cells are tumorigenic in the presence of vGPCR-expressing cells (Fig. 5A) . Surprisingly, shRNA inhibition of ANGPTL4 blocked tumor growth in vivo, demonstrating that ANGPTL4 is an essential paracrine factor in vGPCR sarcomagenesis. Further characterization of these allografts showed that tumors formed in the absence of ANGPTL4 had a reduced number of (CD31-positive) vascular endothelial cells compared with tumors formed in the presence of ANGPTL4 (Fig. 5B) . Moreover, examination of the vascular integrity in tumors formed in the absence of ANGPTL4 revealed a decrease in vessel permeability compared with control animals, measured by the diffusion of rhodamine-dextran or Evans Blue into the tissue (Fig. 5B) . Collectively, these findings suggest that ANGPTL4 is a key molecule in the regulation of vGPCR-induced angiogenesis and vessel permeability in vivo.
To examine in vivo the relative contribution of ANGPTL4 compared with other vGPCR angiogenic factors (13), we stably expressed a shRNA for either VEGF or Angiopoietin 2 (ANG2) in cells stably expressing vGPCR (VEGF sh or ANG2 sh; Fig.  5C ). When we generated allografts in nude mice upon injection of VEGF sh, ANG2 sh, or ANGPTL4 sh1 cells, we found that inhibition of ANGPTL4 potently blocked vGPCR tumorigenesis, similar to that seen upon inhibiting VEGF (Fig. 5C) ; by contrast, inhibition of ANG2 failed to significantly block tumor formation (Fig. 5C ). To determine whether the role of ANGPTL4 and Conditioned media from these cells (CM) or hrANGPTL4 (5 μg/mL) was used to measure FITC-dextran permeability in mature HMVEC monolayers. VEGF (50 ng/mL; 30 min) was used as a control. (B) HMVEC monolayers were grown to confluence on fibronectin-coated slides and then treated for 24 h with PBS (Control), hrANGPTL4 (5 μg/mL), Control CM, or vGPCR CM. Slides were fluorescently stained with anti ZO-1 or anti-β-catenin antibody. (C) GTP-loaded RhoA, Rac1, or Cdc42 levels were determined in HMEC1 treated with PBS, hrANGPTL4 (5 μg/mL), Control CM, or ANGPTL4 CM for 15 min. Treatment with thrombin or sphingosine 1 phosphate (S1P) was used as a control. (D) HMVEC monolayers were grown to confluence on fibronectincoated slides and then treated for 24 h with PBS (Control) or hrANGPTL4 (5 μg/mL). Slides were fluorescently stained with phalloidin. (E) FITC-dextran permeability was determined in mature HMVEC monolayers pretreated with C3 toxin (25 min; 5 μg/mL) or HA1077 (45 min; 1 μM) and then treated with ANGPTL4 (30 min; 5 μg/mL). Treatment with thrombin (30 min; 0.5 U) was used as a control.
VEGF in vGPCR tumorigenesis were redundant, we next made a vGPCR-expressing cell line stably expressing the shRNA for ANGPTL4 and the shRNA for VEGF (ANGPTL4/VEGF sh). Inhibition of both ANGPTL4 and VEGF completely abolished vGPCR tumorigenesis (Fig. 5D) . Collectively, these findings suggest that ANGPTL4-like VEGF-is a critical factor in promoting vGPCR angiogenesis and vascular permeability, and may be an essential target for the treatment of KS.
Discussion
Many pathologic conditions cause a destabilization of the vascular network, resulting in endothelial hyperpermeability, excessive vascular sprouting, and angiogenesis. These pathologic processes are often associated with an imbalance in the function of extracellular angiogenic and/or permeability regulators, and include tumor neovascularization, cancer metastasis, ocular microvascular disease, and vascular malformations (31) . In this regard, KS, an angioproliferative tumor characterized by the presence of prominent angiogenesis and profuse edema, may serve as a model for the dysregulated angiogenesis and vascular leakage characteristic of these other pathological entities.
Emerging evidence suggests that KS development may be the result of dysregulated expression of a single KSHV-encoded gene, vGPCR (16, 32, 33) . This viral protein is expressed in a limited number of cells within KS lesions but is thought to induce tumorigenesis by promoting the secretion of angiogenic and inflammatory molecules (8) . Among all of the cytokines, chemokines, and growth factors secreted by vGPCR-expressing cells, it is believed that VEGF is critical to KS progression through the promotion of neovascularization and vessel permeability (9) (10) (11) (12) . Ongoing clinical trials using therapies targeting VEGF may therefore provide a potent molecular-based therapeutic alternative for the treatment of patients with KS (34). However, despite strong evidence that VEGF is a key player in the development of KS, the relative contribution of this factor-or other angiogenic mediators-is not well understood. Indeed, we report here that vGPCR up-regulation of the VEGF/KDR conduit is not sufficient to explain the potent angiogenesis and vascular permeability characteristic of KS lesions. Rather, we show that vGPCR up-regulation of another angiogenesis-related factor, ANGPTL4, may be an equally essential event in vGPCR sarcomagenesis.
ANGPTL4 is a multifunctional factor with predominant expression in liver, adipose, and ischemic tissues, and is involved in the regulation of lipid metabolism and angiogenesis (19) . Although its secretion has been shown to modulate the disposition of circulating triglycerides by inhibiting lipoprotein lipase, its role in vascular biology is less clear. ANGPTL4 (or specific domains of the protein) has been shown to regulate endothelial cell adhesion (24) and to promote angiogenesis under some circumstances (21, 22, 35) , but also to inhibit angiogenesis in other circumstances (23) (24) (25) (26) . More recently, several studies have suggested similarly discordant functions for this factor in tumor dissemination: whereas systemic ANGPTL4 secretion in mice inhibited melanoma metastasis through inhibition of vascular permeability and tumor cell invasiveness (29), TGFβ-mediated induction of ANGPTL4 by breast cancer cells primed these cells for lung metastasis by increasing the permeability of lung capillaries (28) .
In KS, we show here that vGPCR up-regulation of ANGPTL4 promotes the angiogenic and exudative phenotype characteristic of these lesions. ANGPTL4 was potently up-regulated by vGPCRexpressing endothelial cells in vitro and in vivo. Moreover, ANGPTL4 expression was elevated in all human KS lesions tested, supportive of a critical role of this factor in Kaposi's sarcomagenesis. Inhibition of ANGPTL4 markedly decreased neovascularization and vascular leakage in vitro, and vGPCR tumorigenesis in vivo. Surprisingly, inhibition of both VEGF and ANGPTL4 synergistically blocked vGPCR tumorigenesis compared with inhibition of either factor alone, suggesting that ANGPTL4 may play a more significant role in tumor angiogenesis than previously thought. Given the recent success of molecularbased chemotherapeutics targeting VEGF (36), our findings suggest that ANGPTL4 may prove to be an essential therapeutic approach for the treatment of KS as well as other solid tumors.
Indeed, high levels of ANGPTL4 mRNA have previously been reported in several other cancers, including renal cell carcinoma and glioblastomas (21, 37) . Of note, both of these tumors are associated with dysregulation of the transcription factor hypoxia inducible factor-1 (HIF-1); ANGPTL4 expression is also upregulated in endothelial cells exposed to hypoxia, in ischemic tissues, and in hypoxic areas of solid tumors (21) . As VEGF has been shown to be up-regulated in vGPCR-expressing cells by activation of the transcriptional activity of HIF-1 (14) , it is tempting to speculate that ANGPTL4 may be another vGPCR-induced angiogenic factor transcriptionally controlled through a HIF-1-dependent mechanism. This further suggests that targeting HIF-1 may be an alternative therapeutic approach to down-regulate the secretion of both of these angiogenic mediators. These data may have more broad implications. Our findings support recent observations that production of ANGPTL4 by cancer cells may disrupt vascular endothelial junctions and vascular integrity, facilitating cellular transendothelial passage (28) . In KS, this increased vessel permeability manifests with extravasated erythrocytes and inflammatory cells, whereas in other cancers, ANGPTL4 promotes tumor metastasis. Nonetheless, recent evidence also suggests that the biologic functions of ANGPTL4 may be highly dependent on its microenvironment (26) . Indeed, the diverse and often contradictory functions of ANGPTL4 may be suggestive of a context or tissue-specific activity for this protein (19) . Further characterization of the intracellular signaling pathways that mediate these diverse effects, and the receptor (s) that set them in motion, may ultimately be required to fully appreciate the role of ANGPTL4 in angiogenesis, vascular permeability, and tumor dissemination.
Materials and Methods
Constructs and Reagents. A Tet-on expression system (pBIG-Tet) was used for vGPCR expression. pCEFL Tet REV TA and pBIG AU5 vGPCR were kindly provided by J. Silvio Gutkind (NIDCR, NIH, Bethesda, MD). pCEFL GFP and pCEFL AU5 vGPCR are described in ref. 20 . pcDNA3.1-ANGPTL4-mycHis (full-length human ANGPTL4) was kindly provided by Stéphane Germain (INSERM, Paris, France). For conditioned medium preparation, endothelial cells (HMEC1) were transfected, serum-starved, and treated with doxycycline where corresponding. Twenty-four hours later, supernatants were collected, centrifuged at 1,000 × g for 10 min, and concentrated 10× with centrifugal filters (Millipore). The Rho/Rac/Cdc42 GTPase activation kit was purchased from Cell Biolabs. Human ANGPTL4 and VEGF as well as ANGPTL4 and VEGF ELISA kits were obtained from R&D Systems. Other reagents were purchased as follows: su1498 and HA1077 from Calbiochem; phalloidin from Invitrogen; thrombin and sphingosine 1P from Sigma; and C3 toxin from List Biological Laboratories. Predesigned Control (Scrambled), ANGPTL4, and VEGF siRNA sequences were obtained from Qiagen.
Statistical Analysis. In all cases, results are shown as a mean value ± SD from at least three independent experiments. Western blot scans are representative of at least three independent experiments. Statistical analysis was performed with Prism 4.2 software (GraphPad). ANOVA: ***P < 0.001; **P < 0.01; *P < 0.01.
Additional information can be found in SI Materials and Methods.
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SI Materials and Methods
Cell Lines, Transfections, and in Vitro Tumorigenic Assays. Primary human dermal microvascular endothelial cells (HMVEC) were obtained from Lonza and cultured in EGM-2 medium (Lonza). Immortalized human dermal microvascular endothelial cells (HMEC1) were obtained from the CDC and grown in Gibco MCDB 131 medium (Invitrogen), supplemented with 10% FBS, 10 mM/L L-glutamine, 10 ng/mL epidermal growth factor, 1 μg/mL hydrocortisone, and 1% antibiotic antimycotic. Immortalized murine endothelial cells (SVEC) and SVEC stable cell lines expressing KSHV vGPCR or KSHV vCyc and vFlip are described in ref.
1. shRNA cell lines were generated using pSilencer 2.1-U6 puro vector (Applied Biosystems). Hairpin sequences are as follow: ANGPTL4 (two selected clones; 1 and 2) (sense 5′-GAT-CCAGAAGCTTTCCAAGATGACTTCAAGAGAGTCATCT-TGGAAAGCTTCTTTTTTTGGAAA-3′; and antisense 5′-AG-CTTTTCCAAAAAAAGAAGCTTTCCAAGATGACTCTCTT-GAAGTCATCTTGGAAAGCTTCTG-3′). DNA and siRNA delivery to cells was performed using PolyFect (Qiagen) or HiPerFect (Qiagen), respectively. BrdU incorporation assays and colony growth in soft agar was determined as described in ref.
1.
Western Blot, Immunohistochemistry, and Microscopy. Western blot, immunohistochemistry, and indirect immunofluorescence were performed as described in ref.
1. Antibodies were obtained as follows: ANGPTL4 from Chemicon, ZO1 from Zymed, β-catenin and α-tubulin from Santa Cruz, AU5 from Covance, P-Akt from Cell Signaling, Akt from R&D Systems, and CD31 from BD PharMingen. Polyclonal vGPCR antibody was kindly provided by Gary S. Hayward (Johns Hopkins University, Baltimore, MD) (2). Confocal microscopy was performed using a Zeiss LSM 510 Meta microscope. H&E stainings of the vGPCR experimental and human KS tumors were scanned at 200× using an Aperio T3 Scanscope. qRT-PCR. Total RNA was isolated using the GenElute Mammalian Total RNA Miniprep Kit (Sigma), and reverse transcription was performed using SuperScript III First-Strand Synthesis System (Invitrogen). qRT-PCR was performed on a 96-well/plate ABI7-000HT machine (2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 94°C and 1 min at 60°C) using SYBR Green MasterMix (Applied Biosystems). Primers for human Angptl4 were 5′-CGTGGGGACCTTAACTGTG-3′ (sense) and 5′-TTCCATG-TTTTCCAGAAGATAC-3′ (antisense). GAPDH was used for normalization.
In Vitro Endothelial Cell Migration and Tube Formation (Matrigel) Assays. For (inverse) cell migration, serum-starved 2 × 10 4 /well HMECs were plated in the bottom wells of a Boyden chamber, and a fibronectin-coated polycarbonate membrane (8 μm; Neuroprobe, Inc.) was placed above. The chamber was inverted and incubated for 2 h at 37°C to allow cell attachment. Fifty milliliters of chemotactic sample was added to the top wells. After 6 h, the membrane was stained with Diff-Quick stain (Dade Behring) and analyzed with ImageJ 1.41 (http://rsbweb.nih.gov/ij/ index.html). For tube formation, 100 μL of growth factor-free matrigel was polymerized in 96-well plates. HMEC (2 × 10 4 /well) in 50 μL of 2% FBS MCDB 131 medium were mixed with 50 μL of test sample and added onto the matrigel surface. Eighteen hours later, capillary-like tubule formation was labeled with BD Calcein AM (Becton Dickinson). Digital images were obtained using a video camera system. Total tube length was determined using ImageJ 1.41.
Directed in Vivo Angiogenesis Assay (DIVAA). The DIVAA assay was performed according to manufacturer's protocol (Trevigen). Briefly, 6-wk-old female nude mice were anesthetized with tribromoethanol (i.p., 250 mg/kg). A 1-cm incision was made on both dorsal-lateral surfaces of the animal and two basement membrane extract (BME)-filled angioreactors were implanted on each side. Each angioreactor contained a total of 25 μL BME premixed with 20 μg/mL heparin and 2 μL of test conditioned medium or medium containing recombinant protein. Angioreactors were removed 11 d after implantation. The matrigel was digested with 300 μL of CellSperse solution for 1 h (37°C), and endothelial cells were labeled with FITC-lectin. Fluorescence was measured in 96-well plates (excitation 485 nm, emission 510 nm). Values for cell invasion are calculated as the ratio of relative fluorescent units (RFUs) of the test sample with respect to control sample.
Permeability Assays. HMVEC were seeded on collagen-coated transwells (3-mm-size pore, PTFE; Corning), transfected where corresponding, and allowed to grow as a 3-d-old mature monolayer. Following overnight starvation, 500 μL and 100 μL of test medium were added for 30 min (37°C) to the bottom and top chamber, respectively. A total of 100 μL of 1 mg/mL FITCdextran (molecular weight = 40,000; Invitrogen) was added for 30 min. Fluorescence was quantified using a SpectraMax M5 Microplate Reader (Molecular Devices) with excitation at 494 nm and emission at 521 nm. For in vivo permeability assays, tumor-bearing mice received an i.v. injection of 100 μL Evans blue dye. Thirty minutes later, the animals were killed and perfused with 0.5% paraformaldehyde solution through the left ventricle. Tumors were excised, dried (60°C, 16 h), and weighed before Evans blue extraction in 1 mL of formamide at 55°C for 16 h. Dye content was quantified at 610 nm in a spectrophotometer. For dextran retention, mice-bearing tumors received an i.v. injection of 100 μL rhodamine-dextran (20 mg/mL in PBS; 400 kDa; Sigma). After 2 h, mice were killed and perfused. Tu-mors were frozen and sections were processed for CD31 staining and analysis of vascular leakage using fluorescence microscopy.
Gene Expression Microarray. Total RNA from SVEC or vGPCRexpressing SVEC cells (four RNAs each) was extracted and transcribed to produce biotin-labeled cRNA using TrueLabeling-AMP Linear RNA Amplification Kit (SuperArray Biosciences). Labeled cRNA was purified using SuperArray ArrayGrade cRNA Cleanup Kit and quantified by spectrophotometry. Labeling efficiency was established by serial dilutions on nylon membrane with chemiluminescent detection. Gene expression profiling was done using Oligo GEArray Mouse Angiogenesis Microarray (OMM-024; SuperArray Biosciences), which detects 113 key genes involved in angiogenesis. Prehybridization (2 h) and hybridization (overnight) was done in a hybridization oven (60°C) using 6 μg of labeled cDNA target. High-stringency washing at 60°C (0.1× SSC, 0.5% SDS) was followed by chemiluminescence detection. Array images were recorded using X-ray film and a flatbed desktop scanner to create grayscale (16-bit) files, then analyzed with the GEArray Expression Analysis Suite online software. 
